Revenue
2011
2012
2013
2017
2018
2019
2020
2021
2022
2023
2024
2025
Citius Pharmaceuticals, Inc. (CTXR)
Price$0.5877Cached quote
Net income
2010
2011
2012
2012
2013
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2020
2021
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2012
2013
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 · Dec 31 | 2013 · Sep 30 | 2012 · Dec 31 | 2012 · Sep 30 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $90,000 | $90,000 | $90,000 | $90,000 | $75,000 | $50,000 | — | — | — | — | $0 | — | $0 | $0 | — |
| Gross profit | — | — | — | — | — | — | — | $0 | $0 | — | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | 0.00% | 0.00% | — | — | — | — | — | — | — | — | — |
| Research & development | $9.2M | $11.9M | $14.8M | $17.7M | $12.2M | $8.8M | $125,000 | $6.6M | $2.9M | $2.9M | $1.8M | $574 | $492,136 | — | $705,812 | — | — | — |
| Operating expenses | $38.5M | $42.0M | $36.7M | $33.3M | $23.5M | $17.7M | $15.6M | $13.8M | $10.0M | $7.4M | $3.2M | $653,803 | $1.2M | $28,118 | $1.0M | $19,618 | $25,637 | — |
| Operating income | −$38.5M | −$42.0M | −$36.7M | −$33.3M | −$23.5M | −$17.7M | −$15.6M | −$13.8M | −$10.0M | −$7.4M | −$3.2M | −$653,803 | −$1.2M | −$28,118 | −$1.0M | −$19,618 | −$25,637 | — |
| Operating margin | — | — | — | −37,017.83% | −26,146.55% | −19,678.54% | −17,331.51% | −18,385.52% | −19,972.62% | — | — | — | — | — | — | — | — | — |
| EBITDA | −$38.2M | −$42.0M | −$36.7M | −$33.3M | −$23.5M | −$17.7M | −$15.6M | −$13.8M | −$10.0M | −$7.4M | −$3.2M | — | — | — | — | — | — | — |
| EBITDA margin | — | — | — | −37,014.58% | −26,144.89% | −19,677.60% | −17,330.52% | −18,383.19% | −19,967.36% | — | — | — | — | — | — | — | — | — |
| Net income | −$39.7M | −$39.4M | −$32.5M | −$33.6M | −$23.1M | −$17.5M | −$15.6M | −$12.5M | −$10.4M | −$8.3M | −$2.9M | −$737,727 | −$1.3M | −$31,369 | −$1.0M | −$22,006 | −$26,341 | −$15,500 |
| Net profit margin | — | — | — | −37,378.50% | −25,616.04% | −19,497.87% | −17,291.27% | −16,715.52% | −20,769.91% | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$3.38 | -$5.97 | -$5.57 | -$5.75 | -$5.75 | -$11.25 | -$19.25 | -$29.25 | -$47.25 | -$57.25 | -$34.25 | -$15.00 | -$26.25 | $0.00 | -$22.50 | $0.00 | $0.00 | — |
| Diluted EPSper diluted share | -$3.38 | -$5.97 | -$5.57 | -$5.75 | -$5.75 | -$11.25 | -$19.25 | -$29.25 | -$47.25 | -$57.25 | -$34.25 | -$15.00 | -$26.25 | $0.00 | -$22.50 | $0.00 | $0.00 | — |
Owners
Reported shareholders
≈1.49%of listed shares
Mazur Leonard L410.21K shares · Aug 8, 2025
View holders
| Holder | % owned |
|---|---|
Mazur Leonard L | ≈1.49%410.21K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.79%215.54K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.72%197.36K shares |
Miller Financial Services LLC | 0.47%130K shares |
CITADEL ADVISORS LLC | 0.46%124.91K shares |
JANE STREET GROUP, LLC | 0.45%122.84K shares |
HOLUBIAK MYRON Z | ≈0.29%79.69K shares |
VANGUARD FIDUCIARY TRUST CO | 0.28%77.76K shares |
BlackRock, Inc. | 0.25%69.85K shares |
NORTHERN TRUST CORP | 0.23%62.74K shares |
Bartushak Jaime | ≈0.22%60.35K shares |
XTX Topco Ltd | 0.22%59.2K shares |
Asset Advisory Group, Inc. | 0.21%59.01K shares |
BostonPremier Wealth LLC | 0.10%28K shares |
UBS Group AG | 0.10%26.34K shares |
LPL Financial LLC | 0.09%25.45K shares |
STATE STREET CORP | 0.08%23.27K shares |
Virtu Financial LLC | 0.08%20.84K shares |
Arkadios Wealth Advisors | 0.07%20K shares |
TWO SIGMA INVESTMENTS, LP | 0.06%17.49K shares |
Percentages use 27.45M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data